Archit Organosys (524640)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Low valuation: P/E of 9.99 and P/B of 1.49 against book value of ₹33.12.
• Strong growth: sales up 48.43% and profit up 140.59%, with PEG of 0.11.
• Piotroski F-Score of 7/9 indicates reasonable financial health.
• ROE of 12.13% and ROCE of 10.85% are respectable for a small-cap.
• Dividend yield of 1.28% provides a modest income cushion.

Concerns

• Commodity chemicals business likely lacks pricing power and has a narrow moat.
• Debt-to-equity is not available, so leverage risk cannot be assessed.
• Promoter holding is not disclosed, leaving governance and alignment unclear.
• Net margin is thin: ₹2 crore profit on ₹38 crore sales, making earnings vulnerable to cost or price swings.

AI Analysis

At first glance, Archit Organosys looks like the kind of small-cap that Graham would at least examine: a ₹101 crore market cap against a book value of ₹33.12 per share, trading at 1.49 times book and under 10 times earnings. The trailing P/E of 9.99 and a PEG of 0.11 suggest the market is not paying up for growth. And there is growth: sales up 48.43% and profits up 140.59%. Whenever profits outpace sales by that much, I ask whether it is sustainable or simply operating leverage from a small base. The latest quarter's ₹38 crore in sales and ₹2 crore net profit show the scale; annualised, that is broadly consistent with the current valuation, but the net margin is thin. An F-Score of 7 out of 9 is a decent health signal, and a 12.13% ROE with a 10.85% ROCE are respectable. The 1.28% dividend yield provides a small return while I wait. But I cannot ignore what I do not know: debt-to-equity is not available, and promoter holding is not disclosed. In commodity chemicals, pricing power is weak and earnings are tied to the cycle. This is not a wonderful franchise; it is a potentially cheap, growing player in an unforgiving industry. I would need the balance sheet and cash flow before acting. If growth continues and debt stays low, the current price may be attractive. But one good quarter and one high-growth year do not make a great investment. I would watch the next few quarters, the commodity cycle, and whether margins can hold. For now, it is interesting but not yet a clear buy. As Graham said, price is what you pay, value is what you get; I need more evidence that the value is truly there.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer